Implementer: Partners In Health
Site: National Center for TB Problems of the MOHSD of Kazakhstan, Almaty City, Astana City, Almaty Oblast, Zhambyl Oblast and Akmolinskaya Oblast
Patients treated with:
| Bedaquiline | 483 |
|---|---|
| Delamanid | 267 |
Enrollment in the observational study is now complete and Kazakhstan is participating in the endTB and endTB-Q trials.
Implementer: Partners In Health
Site: National Center for TB Problems of the MOHSD of Kazakhstan, Almaty City, Astana City, Almaty Oblast, Zhambyl Oblast and Akmolinskaya Oblast
Kazakhstan, a Central Asian country, has one of the highest numbers of MDR-TB patients in the world. 26% of newly diagnosed TB patients and 44% of retreatment cases have MDR-TB. PIH supported the National Tuberculosis Program (NTP) in scaling up MDR-TB treatment, especially in the prison sector, leading to enrolment of more than 900 patients across the country.
PIH maintains a close relationship with the NTP and has contributed to the development of national decree and guidelines on MDR-TB that have been approved by the Ministry of Health for scale-up.
